Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTAA91 in Refractory Systemic Sclerosis
NCT07000682Phase 1Recruiting
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UTAA91 in systemic sclerosis (SSc). Primary endpoint: Adverse events at 1 year. Started May 2025; status: recruiting.
02
Drugs
UTAA91
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07000682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07000682.